This Project Grant award of $1,857,842 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund a 12-month randomized controlled trial. The trial will test the hypothesis that administering the drug romosozumab, followed by a single dose of zoledronic acid, to amenorrheic adolescents and young adults with functional hypothalamic amenorrhea (FHA) can improve their bone mineral...
This federal Project Grant award of $465,663 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to optimize the bone surface targeting of therapeutic antibodies for treating osteoporosis. The key objectives are to: 1) Optimize the pharmacokinetics and pharmacodynamics of an anti-sclerostin antibody in healthy and osteoporosis model mice, and conduct a...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to investigate the mechanisms by which mechanical and hormonal signals are integrated within bone cells to stimulate bone formation. The total award amount is $175,948 and will be performed over 5 years from June 1, 2025 to May 31, 2030. The research aims to identify how the focal...
This Project Grant award, valued at $359,133.00, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports the generation of new genetic tools to enable more targeted and specific analysis of tendon and musculoskeletal tissues in mice. The goal is to develop constitutive and inducible FLP alleles that can be used in combination with existing...
This federal Project Grant award, valued at $1,938,605.00 and awarded on August 19, 2024 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to define the mechanisms by which the X-linked chromatin modifying enzyme KDM5C regulates bone mass in females. The primary objectives are to investigate how the loss of KDM5C affects osteoclast function, osteoclast-osteoblast communication, and osteoclast energy metabolism. The research team will also examine the...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
This federal Project Grant award, with ID R01AR085352, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $665,792 award, with a project period from January 1, 2025 to March 31, 2029, will fund a study to quantify bone mineral density and trabecular bone score, assess dietary intake and biomarkers in relation to bone outcomes, and measure psychophysiological...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) Federal Grant Program, supports research into the mechanisms of inflammatory osteoblastogenesis and bone formation. The $688,634 award to The Hospital For Special Surgery Fund, Inc. (doing business as HSS Foundation) will fund a 5-year investigation into how the constitutive type-I interferon response in osteoblasts suppresses bone formation, and how this is influenced by aging and...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA Program 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, provides $176,040.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on glucocorticoid toxicity and its impact on clinical outcomes and quality-of-life in vasculitis patients. The key objectives of this 5-year project are to: 1)...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $599,693 to The Hospital For Special Surgery Fund, Inc. (HSS Foundation) from August 1, 2024 to July 31, 2029. The award supports research to elucidate molecular pathways and mechanisms that regulate myeloid cell function and osteoclastogenesis, with the goal of developing new...
This Project Grant award of $1,175,680.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to assess the potential benefits of combined anabolic therapy versus a single-drug approach for treating postmenopausal osteoporosis. The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will conduct a comparative study to determine if combining the anabolic drugs teriparatide and romosozumab can improve skeletal parameters more than a 12-month course of romosozumab alone in high-risk postmenopausal women. The successful completion of this research has the potential to fundamentally shift the standard of care for managing established osteoporosis and introduce a new concept in osteoporosis treatment. The award period runs from September 23, 2024 to August 31, 2027.